

Ryan B Corcoran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1520336/publications.pdf>

Version: 2024-02-01

72
papers

11,805
citations

66343

42
h-index

82547

72
g-index

76
all docs

76
docs citations

76
times ranked

17040
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. <i>Cancer Discovery</i> , 2012, 2, 227-235.	9.4	852
2	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	30.7	809
3	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686
4	Application of Cell-free DNA Analysis to Cancer Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 1754-1765.	27.0	634
5	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	9.4	448
6	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	1.6	430
7	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	9.4	384
8	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
9	<i>STAT3</i> Plays a Critical Role in <i>KRAS</i> -Induced Pancreatic Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 5020-5029.	0.9	358
10	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	7.1	353
11	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in <i>KRAS</i> Mutant Cancer Models. <i>Cancer Cell</i> , 2013, 23, 121-128.	16.8	343
12	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 147-153.	9.4	338
13	A combinatorial strategy for treating <i>KRAS</i> -mutant lung cancer. <i>Nature</i> , 2016, 534, 647-651.	27.8	337
14	<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the <i>BRAF</i> V600E Mutation. <i>Science Signaling</i> , 2010, 3, ra84.	3.6	314
15	Targeting Alterations in the RAF-MEK Pathway. <i>Cancer Discovery</i> , 2019, 9, 329-341.	9.4	282
16	Therapeutic strategies to target RAS-mutant cancers. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 709-720.	27.6	274
17	Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> -Mutant Colorectal Cancer through MAPK Pathway Alterations. <i>Cancer Discovery</i> , 2015, 5, 358-367.	9.4	265
18	Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to <i>KRAS</i> G12C Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 1633-1643.	7.0	263

#	ARTICLE	IF	CITATIONS
19	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	9.4	256
20	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	28.9	256
21	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	9.4	254
22	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	9.4	243
23	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. <i>Cancer Discovery</i> , 2021, 11, 1913-1922.	9.4	243
24	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
25	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	7.0	178
26	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. <i>Journal of Clinical Investigation</i> , 2011, 121, 4311-4321.	8.2	177
27	Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. <i>Cancer Discovery</i> , 2014, 4, 452-465.	9.4	169
28	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015, 5, 1271-1281.	9.4	162
29	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. <i>Science Translational Medicine</i> , 2013, 5, 196ra98.	12.4	124
30	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 396-404.	7.0	121
31	Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. <i>Oncotarget</i> , 2011, 2, 336-346.	1.8	114
32	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	13.2	112
33	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016, 76, 4504-4515.	0.9	91
34	Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7089-7097.	7.0	79
35	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	3.7	73
36	Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. <i>Nature Communications</i> , 2020, 11, 2971.	12.8	71

#	ARTICLE	IF	CITATIONS
37	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67
38	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	7.0	64
39	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 439-449.	7.0	64
40	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> ^{V600E} Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	9.4	61
41	Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. <i>Genome Medicine</i> , 2017, 9, 37.	8.2	52
42	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , 2020, 38, 420-425.	17.5	48
43	<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505.	9.4	46
44	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 719-727.	7.0	46
45	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2466-2476.	7.0	39
46	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	5.4	36
47	Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2022, 128, 2193-2204.	4.1	35
48	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. <i>Cell Reports</i> , 2022, 39, 110993.	6.4	34
49	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	3.0	30
50	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	9.4	30
51	Liquid biopsy versus tumor biopsy for clinical-trial recruitment. <i>Nature Medicine</i> , 2020, 26, 1815-1816.	30.7	29
52	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	4.6	25
53	Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with <i>BRAF</i> Mutation and 5-year Overall Survival. <i>Radiology Imaging Cancer</i> , 2020, 2, e190084.	1.6	22
54	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. <i>Cancer Medicine</i> , 2018, 7, 2934-2942.	2.8	21

#	ARTICLE	IF	CITATIONS
55	New therapeutic strategies for BRAF mutant colorectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 650-9.	1.4	21
56	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	17
57	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 207-215.	3.8	17
58	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	3.7	16
59	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	3.0	16
60	Cell-free DNA Analysis in Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 501-502.	27.0	12
61	Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048405.	0.7	11
62	Fast-TRKing Drug Development for Rare Molecular Targets. <i>Cancer Discovery</i> , 2017, 7, 934-936.	9.4	9
63	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?. <i>JAMA Oncology</i> , 2020, 6, 823.	7.1	9
64	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. <i>Oncologist</i> , 2021, 26, e963-e970.	3.7	9
65	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	7.0	8
66	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	4.1	7
67	Circulating Tumor DNA: Clinical Monitoring and Early Detection. <i>Annual Review of Cancer Biology</i> , 2019, 3, 187-201.	4.5	6
68	Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Response. <i>Clinical Cancer Research</i> , 2021, 27, 6614-6615.	7.0	4
69	Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast. <i>Cancer Discovery</i> , 2018, 8, 1213-1215.	9.4	3
70	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	3.8	3
71	Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation. <i>Cancer Research</i> , 2022, 82, 5162-5162.	0.9	1
72	Abstract LB003: Combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients: Correlative studies from a phase 2 trial. <i>Cancer Research</i> , 2022, 82, LB003-LB003.	0.9	1